Cadrenal Therapeutics (CVKD) CEO Quang Pham Sells $28K of Stock
Cadrenal Therapeutics Chairman, CEO, and Interim CFO Quang Pham has executed another stock sale, unloading 9,029 shares of CVKD.
Reviewed by automated data checks against the source filing. How we make and check alerts
Quang Pham, Chairman, CEO and Interim CFO at Cadrenal Therapeutics, Inc. ($CVKD), sold 9,029 shares at an average price of $3.05, worth about $27,538.45, on June 26, 2026. The trade was reported to the SEC in a Form 4 filing and was made under a pre-arranged Rule 10b5-1 trading plan.
Since the trade, $CVKD is up 10.2% after 1 week, down 32.5% after 1 month and down 64.3% to date (from the $3.05 close on Jun 26, 2026).
CVKD
Cadrenal Therapeutics, Inc.
Key Points
- Cadrenal Therapeutics CEO Quang Pham sold 9,029 shares of the company on June 26, 2026, at a price of $3.05 per share.
- The transaction totals $27,538.45 and was executed under a pre-arranged trading plan.
- This sale adds to a busy month of June transactions by the chief executive officer.
Get $CVKD trade alerts by text
We text you when insiders, Congress or big funds trade $CVKD. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Cadrenal Therapeutics, Inc. alert may contain errors. Disclosures
CEO Quang Pham Unloads More CVKD Shares
Cadrenal Therapeutics, Inc. (NasdaqCM: CVKD) chief executive Quang Pham has trimmed his stake further, parting with 9,029 shares on June 26, 2026. Regulatory filings show the latest transaction brought in $27,538.45 at a price of $3.05 per share. The executive carried out this trade under a pre-arranged trading plan, adding to a busy string of disposals through the month.
A Busy Month of Insider Activity
This latest move continues a busy sequence of sales by the top executive throughout June. Just days earlier on June 16, 2026, Pham sold 3,613 shares at $3.18 each for a total of $11,489.34 in a planned move. Right after that on June 17, 2026, he disposed of 513 shares at an average price of $3.16 to fetch $1,621.08. Earlier in the month on June 12, 2026, Pham unloaded 12,996 shares in two separate transactions at $3.94 apiece, each valued at $51,204.24. He also sold 3,666 shares on June 15, 2026, at $3.58 per share for a total of $13,124.28. These planned and open-market sales form part of an active series of dispositions by the company leader.
CVKD Stock Background
Cadrenal Therapeutics shares trade on the NasdaqCM exchange under the ticker CVKD. The biopharmaceutical firm carries a small market capitalization of about $3.89 million, reflecting its micro-cap status in the healthcare sector. The stock has experienced wide swings over the past year, trading between a 52-week low of $1.00 and a high of $14.64. Insider transactions of this nature are common among executives managing personal financial planning or diversification strategies and do not inherently signal a directional outlook from management.
About Cadrenal Therapeutics
Based in Ponte Vedra, Florida, Cadrenal Therapeutics focuses on developing novel treatments for life-threatening cardiovascular and immune conditions. Its pipeline includes Tecarfarin, an oral vitamin K antagonist aimed at preventing blood clots for patients with specific cardiac devices or kidney disease. The enterprise works to address serious medical needs in specialized cardiology markets with few alternative therapies.
What Lies Ahead
Market participants tracking Cadrenal Therapeutics will monitor future regulatory filings to see if executive selling continues or stabilizes. Additional insights will arrive with the company's next scheduled financial updates. As always, insider sales filed through the SEC look backward at completed transactions and do not represent a formal recommendation regarding the stock.
Related Filing Alerts
Source: Quang Pham's Form 4 filing on $CVKD (Jun 26, 2026). Find the original filing: CVKD Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts